184 related articles for article (PubMed ID: 20516562)
1. Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
Cunyat F; Ruiz L; Marfil S; Puig T; Bofill M; Blanco J; Clotet B; Cabrera C
Antivir Ther; 2010; 15(3):431-6. PubMed ID: 20516562
[TBL] [Abstract][Full Text] [Related]
2. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
Colonno R; Rose R; McLaren C; Thiry A; Parkin N; Friborg J
J Infect Dis; 2004 May; 189(10):1802-10. PubMed ID: 15122516
[TBL] [Abstract][Full Text] [Related]
3. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
4. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
Mittal S; Bandaranayake RM; King NM; Prabu-Jeyabalan M; Nalam MN; Nalivaika EA; Yilmaz NK; Schiffer CA
J Virol; 2013 Apr; 87(8):4176-84. PubMed ID: 23365446
[TBL] [Abstract][Full Text] [Related]
5. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Weinheimer S; Discotto L; Friborg J; Yang H; Colonno R
Antimicrob Agents Chemother; 2005 Sep; 49(9):3816-24. PubMed ID: 16127058
[TBL] [Abstract][Full Text] [Related]
6. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
[TBL] [Abstract][Full Text] [Related]
8. HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
Scudeller L; Torti C; Quiros-Roldan E; Patroni A; Lo Caputo S; Moretti F; Mazzotta F; Donati E; Vivarelli A; Carosi G;
J Antimicrob Chemother; 2003 Nov; 52(5):776-81. PubMed ID: 14563897
[TBL] [Abstract][Full Text] [Related]
9. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
Lam E; Parkin NT
Clin Infect Dis; 2003 Nov; 37(9):1273-4. PubMed ID: 14557976
[No Abstract] [Full Text] [Related]
10. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
[TBL] [Abstract][Full Text] [Related]
11. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.
Sista P; Wasikowski B; Lecocq P; Pattery T; Bacheler L
J Clin Virol; 2008 Aug; 42(4):405-8. PubMed ID: 18472298
[TBL] [Abstract][Full Text] [Related]
12. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
13. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
Murphy MD; Marousek GI; Chou S
J Clin Virol; 2004 May; 30(1):62-7. PubMed ID: 15072756
[TBL] [Abstract][Full Text] [Related]
14. [Viral resistance and genetic barrier of atazanavir].
Mendoza CD; Garrido C; Treviño A; Anta L; Poveda E; Soriano V
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():28-33. PubMed ID: 20116614
[TBL] [Abstract][Full Text] [Related]
15. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
[TBL] [Abstract][Full Text] [Related]
16. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
17. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
[TBL] [Abstract][Full Text] [Related]
18. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
Seminari E; Guffanti M; Villani P; Gianotti N; Cusato M; Fusetti G; Galli A; Castagna A; Regazzi M; Lazzarin A
Eur J Clin Pharmacol; 2005 Aug; 61(7):545-9. PubMed ID: 16041598
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
Zachary KC; Hanna GJ; D'Aquila RT
Clin Infect Dis; 2001 Dec; 33(12):2075-7. PubMed ID: 11700580
[TBL] [Abstract][Full Text] [Related]
20. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
